Gelonghui May 27 丨 Hongyuan Pharmaceutical (301246c3catfishspecialround.SZ) said on the investor interaction platformc3catfishspecialround, the company currently has no products prepared through synthetic biology technology. in additionc3catfishspecialroundThe "Wuhan R & D Center Expansion Project" implemented by Hubei Hongyuan Chemical Technology Co., Ltd., a wholly-owned subsidiary of the company, will build chemical research platforms including impurity research, crystal form research, synthetic biology research, asymmetric synthesis and continuous flow, as well as preparation research technology platforms such as tablets, capsules, sustained and controlled release and injections. Currently, the project has not yet been completed. The company's R & D progress and development plan have been disclosed in the section 4, Main Business Analysis (4. R & D Investment) of Section 3 "Management Discussion and Analysis" of the 2023 annual report. Please pay attention to the company's regular reports for subsequent progress and specific circumstances.
c3catfishspecialround| Hongyuan Pharmaceutical (301246.SZ): There are currently no products prepared through synthetic biology technology
- Ph365 com
-
- nftgamelikedungeonswap| CICC: Raise cloud music target price to HK$114 to maintain "outperform industry" rating
- megamillionsjackpotwinningnumbers| Bank of China: It plans to invest 21.5 billion yuan in the National Integrated Circuit Industry Investment Fund Phase III Co., Ltd.
- vegazcasinonodepositbonus| Zhaolong Interconnect: Net profit for the first quarter was 17.6062 million yuan, a year-on-year increase of 11.91%
- earnfreecryptogames| What is the size of the 2022 Honda vezel Binzhi body?
- spinforcashrealmoneyslot| Taihe Xincai (002254.SZ): The net profit for the first quarter is 333 million yuan, and it is planned to be 3 yuan for 10 shares
- crashofcarsonline| What are the reasons and solutions for Camry's automobile air conditioners with half hot air and half cold air?
- digdugarcade| CITIC Construction Investment: Strategically, we can still be optimistic about A-shares and still allocate dividends to bottom positions
- luckydreamscasinonodepositbonuscodes| Evergrande Automobile: It plans to sell 58.5% of its shares, suspend production of Tianjin factory, and lack of funds remains to be resolved
- cps1games| Guanghong Technology: The shares held by the company's major shareholders and senior executives have not participated in the pledge or lending business
- freevideopokerforfun| Yingmei Holdings (02028.HK) appoints Sun Baoyuan as independent non-executive director
- jili777 com ph
-